Related Experiment Video

Updated: Feb 21, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K

The assessment of new anti-tuberculosis drugs for a paediatric indication

P R Donald1

  • 1Department of Paediatrics and Child Health, University of Stellenbosch and Tygerberg Children's Hospital, Tygerberg, South Africa. prd@sun.ac.za

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
|October 26, 2007
PubMed

Insights

Assessing new anti-tuberculosis agents in children is challenging due to disease spectrum and lack of objective criteria. However, evaluating pharmacokinetics and toxicity in pediatric populations is essential for developing effective tuberculosis treatments.

Area of Science:

  • Medical Research
  • Infectious Diseases
  • Pediatrics

Background:

  • A promising pipeline of over 20 new anti-tuberculosis agents is in development, with some entering clinical trials.
  • Childhood tuberculosis (TB) represents a substantial portion of the global TB burden, especially in developing regions.
  • Currently, there is no established protocol for evaluating anti-TB drugs in pediatric populations.

Purpose of the Study:

  • To discuss the feasibility of assessing new anti-tuberculosis agents in children.
  • To highlight the challenges in evaluating drug efficacy in pediatric TB.
  • To emphasize the necessity of pharmacokinetic and toxicity assessments in children.

Main Methods:

  • Literature review and expert discussion on pediatric TB drug assessment.
  • Analysis of challenges related to disease heterogeneity in childhood TB.
  • Consideration of pharmacokinetic and toxicity evaluation methodologies.

Main Results:

  • Assessing the efficacy of new anti-TB agents in children is deemed very difficult.
  • Challenges include the wide spectrum of pediatric TB diseases and limited objective response criteria.
  • Despite efficacy assessment difficulties, pharmacokinetic and toxicity studies in children are crucial.

Conclusions:

  • Establishing a clear pathway for pediatric anti-TB drug assessment is urgently needed.
  • Pharmacokinetic and toxicity evaluations in diverse pediatric age groups are essential.
  • Further research is required to develop reliable methods for assessing anti-TB drug efficacy in children.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.1K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.3K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
346
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
368
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
269
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
298
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
660
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
559